SCHEMBL2964755

SCHEMBL2964755

CNc1ncc(Br)c(-c2cccs2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MERTK Q12866 1/20 0.44
ADORA1 P30542 4/20 0.41
ADORA2A P29274 3/20 0.41
CDK1 P06493 2/20 0.40
KDR P35968 2/20 0.40
ALDH1A1 P00352 5/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
CASP1 P29466 4/20 0.40
CASP7 P55210 4/20 0.40
HSD17B10 Q99714 4/20 0.40
CYP1A2 P05177 4/20 0.40
CYP3A4 P08684 3/20 0.40
USP2 O75604 3/20 0.40
CYP2C9 P11712 3/20 0.40
HIF1A Q16665 3/20 0.40
GAA P10253 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13202503 0.79 MEN1 (0.46) MERTKADORA1ADORA2ACDK1KDR
SCHEMBL2967774 0.78 CDK1 (0.46) MERTKADORA1ADORA2ACDK1KDR
SCHEMBL14879279 0.77 CDK1 (0.47) MERTKADORA1ADORA2ACDK1KDR
SCHEMBL2965386 0.76 ADORA2A (0.50) ADORA1ADORA2AALDH1A1MEN1KMT2A
SCHEMBL14626213 0.76 RPS6KB2 (0.47) ADORA1ADORA2AALDH1A1MEN1KMT2A
SCHEMBL14590439 0.76 ADORA2A (0.54) ADORA1ADORA2AALDH1A1MEN1KMT2A
SCHEMBL2964963 0.75 CDK1 (0.43) MERTKADORA1ADORA2ACDK1KDR
SCHEMBL9438562 0.69 ALDH1A1 (0.46) ADORA1ADORA2AALDH1A1MEN1KMT2A
SCHEMBL12715485 0.69 DHFR (0.45) ADORA1ADORA2AALDH1A1MEN1KMT2A
SCHEMBL3971542 0.67 ADORA2A (0.53) ADORA1ADORA2ACDK1KDRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8557996-B2 Heteroaryl-substituted alkyne compounds and method of use AMGEN INC. (US) 2013-10-15 US disclosed
EP-1802586-B1 HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE AMGEN INC (US) 2013-04-24 EP disclosed
US-7776869-B2 Heteroaryl-substituted alkyne compounds and method of use AMGEN INC. (US) 2010-08-17 US disclosed
US-20100160283-A1 HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE AMGEN INC. (US) 2010-06-24 US disclosed
EP-1802586-A2 HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE Amgen Inc. (US) 2007-07-04 EP disclosed
US-20060217380-A1 Heteroaryl-substituted alkyne compounds and method of use AMGEN INC. 2006-09-28 US disclosed
WO-2006044823-A2 HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE AMGEN INC. (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160283-A1 HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE IRAK3, IRAK1, MAP3K1 MERTK 943/4885ADORA1 302/4885ADORA2A 169/4885
US-20060217380-A1 Heteroaryl-substituted alkyne compounds and method of use IRAK3, IRAK1, MAP3K1 MERTK 943/4885ADORA1 302/4885ADORA2A 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.